Annexin V, Human Recombinant: Gold-Standard Apoptosis Detection Reagent

Executive Summary: Annexin V, human recombinant binds exposed phosphatidylserine (PS) with nanomolar affinity in a Ca²⁺-dependent manner, enabling early and quantitative apoptotic cell detection [APExBIO product]. It competitively inhibits blood coagulation by blocking prothrombinase complex formation on cellular membranes (Van Heerde et al. 1994). The reagent remains stable at -20°C for extended storage and is compatible with multiple labeling strategies. Its performance is validated in both biochemical and cell-based models, supporting applications from basic research to translational workflows [NortriptylinePharma]. APExBIO's formulation (SKU K2064) is supplied at 1 mg/mL in PBS, pH 7.4, ready for custom conjugation or direct use in competition binding assays.

Biological Rationale

Annexin V is a member of the annexin family, comprising at least 13 Ca²⁺-dependent phospholipid-binding proteins (Van Heerde et al. 1994). Under physiological conditions, phosphatidylserine (PS) is restricted to the inner leaflet of the plasma membrane. Early in apoptosis, PS translocates to the outer leaflet, providing a cell-surface biomarker for apoptotic cells. Annexin V binds selectively and with high affinity to externalized PS, making it a gold-standard probe for early apoptosis detection (see also: OlopatadineOnline—this article expands on performance criteria and labeling strategies). The specificity of Annexin V-PS interaction underpins its widespread adoption for apoptosis assays in cancer, neurodegenerative, and cardiovascular research models.

Mechanism of Action of Annexin V, Human Recombinant

Annexin V operates through Ca²⁺-dependent binding to negatively charged PS on cellular membranes. This binding is rapid, reversible, and highly specific to PS in the presence of >1 mM CaCl₂ at neutral pH [APExBIO product]. In apoptosis assays, Annexin V labels cells at the stage where PS is externalized but the plasma membrane remains intact, distinguishing early apoptotic from necrotic cells. In coagulation biochemistry, Annexin V blocks assembly of prothrombinase and tenase complexes by masking PS, thereby inhibiting factor Xa and thrombin formation (Van Heerde et al. 1994). The protein can also inhibit phospholipase A1 activity by competing for PS. Use of unlabeled Annexin V allows for custom detection tag conjugation or competition assays against labeled derivatives such as FITC or PE conjugates.

Evidence & Benchmarks

• Annexin V binds to extracellular PS with a dissociation constant (K_d) of 15.5 ± 3.3 nM on human endothelial cells (HUVEC) at 37°C in PBS, pH 7.4, with 2 mM CaCl₂ (Van Heerde et al. 1994).
• Each HUVEC expresses approximately 8.8 (±3.9) × 10⁶ Annexin V binding sites under both quiescent and stimulated conditions (Van Heerde et al. 1994).
• Annexin V inhibits factor Xa formation (extrinsic pathway) with an IC₅₀ of 43 ± 30 nM and (intrinsic pathway) with an IC₅₀ of 33 ± 24 nM under in vitro conditions (Van Heerde et al. 1994).
• The IC₅₀ for inhibition of thrombin generation by prothrombinase complex on HUVEC is 16 ± 12 nM at 37°C (Van Heerde et al. 1994).
• Annexin V is present in human plasma at <5 ng/mL under physiological conditions (Van Heerde et al. 1994).

Applications, Limits & Misconceptions

Annexin V, human recombinant is used for early apoptosis detection, flow cytometry, fluorescence microscopy, and competitive binding assays in cell death research (Annexin V FITC—this article details advanced assay design, while the current guide focuses on unlabeled/competition formats). It is also used to study coagulation mechanisms and as a PS-dependent anticoagulant in biochemical workflows. The reagent is suitable for custom conjugation with fluorophores (e.g., FITC, PE, Cy3) or biotin for multiplexed detection (Annexin V Biotin—offers practical guidance for labeling; this article elaborates on physiological benchmarks).

Common Pitfalls or Misconceptions

• Annexin V does not detect late-stage apoptosis or necrosis unless paired with a membrane-impermeant dye (e.g., PI or 7-AAD); it is not a viability marker alone.
• The binding is strictly Ca²⁺-dependent; omission or chelation of Ca²⁺ (e.g., with EDTA) abrogates PS recognition.
• Annexin V, human recombinant is intended for research use only and is not validated for clinical diagnostics or therapeutics.
• False positives can occur if cells are mechanically disrupted or excessively handled, leading to artifactual PS externalization.
• Annexin V binding is reversible; prolonged incubation or washing without Ca²⁺ may result in signal loss.

Workflow Integration & Parameters

APExBIO's Annexin V (K2064) is supplied as a 1 mg/mL solution in PBS (pH 7.4), stored at -20°C for long-term stability. Lyophilized product can be reconstituted in PBS or ultrapure water to 1–5 mg/mL. Prior to use, centrifuge vials at >10,000 × g for 1–2 min to ensure homogeneity. For labeling, standard protocols apply for FITC, PE, or biotin conjugation. In flow cytometry, typical working concentrations are 1–5 μg/mL; for competition assays, titration against labeled Annexin V is recommended. Always supplement buffers with 2–2.5 mM CaCl₂ for optimal binding. Refer to the Annexin V, human recombinant product page for storage and handling protocols.

Conclusion & Outlook

Annexin V, human recombinant (SKU K2064) from APExBIO delivers validated, quantitative detection of early apoptosis via high-affinity, Ca²⁺-dependent PS binding. Its robust performance in both biochemical inhibition and cell-based labeling is substantiated by peer-reviewed evidence and internal benchmarking. As apoptosis research expands into complex disease models and high-content screening, unlabeled Annexin V provides a flexible platform for custom assay design and multiplexed readouts. For comparative assay optimization or advanced troubleshooting, see Annexin V FITC and Annexin V Biotin—this article updates physiological benchmarks and clarifies unlabeled applications.